The pivotal factors influencing the selection of initial treatment options for advanced NSCLC encompass the histological type, distinguishing between squamous and non-squamous varieties, the presence of driver gene mutations, such as EGFR, ALK, and ROS1 mutations, and the expression of PD-L1. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.